StockData
FLNANasdaqPharmaceutical PreparationsFiscal year ends December 31

FILANA THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$0.68−0.02 (-3.06%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 11, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 29, 2026Before market open–$-0.18–
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026Before market open–$-0.21–
Q4 FY2025
Ended Dec 31, 2025
Mar 12, 2026Before market open–$-0.26–
Q3 FY2025
Ended Sep 30, 2025
Nov 12, 2025Before market open–$-0.22–
Q2 FY2025
Ended Jun 30, 2025
Aug 14, 2025Before market open–$-0.92–
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025Before market open–$-0.48–
Q4 FY2024
Ended Dec 31, 2024
Mar 3, 2025Before market open–$-0.57–
Q3 FY2024
Ended Sep 30, 2024
Nov 7, 2024Before market open–$-0.58–
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024Before market open–$0.13–
Q1 FY2024
Ended Mar 31, 2024
May 10, 2024After market close–$-0.43–
Q4 FY2023
Ended Dec 31, 2023
Feb 28, 2024Before market open–$-0.50–

Company guidance

Outlook given with results on Jul 29, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Net cash used in operationssecond-half 2026$11.00M to $15.00MLowered
unrestricted cashyear-end 2026$36.00M to $40.00MRaised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Filana Therapeutics filed with the SEC